Balstilimab, Potential Cervical Cancer Treatment, Placed on Fast Track
News
The U.S. Food and Drug Administration (FDA) has now given fast track status to Agenus’ balstilimab — both alone and in combination — as an immunotherapy candidate for advanced metastatic cervical cancer. This designation, given ... Read more